Skip to main content

Vaginal Atrophy

5
Pipeline Programs
7
Companies
10
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
0
1
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Stratpharma
StratpharmaSwitzerland - Basel
1 program
1
7-940Phase 41 trial
Active Trials
NCT07346287Recruiting10Est. Apr 2026
Pfizer
PfizerNEW YORK, NY
1 program
1
Bazedoxifene/Conjugated EstrogenPhase 32 trials
Active Trials
NCT01634789Terminated2Est. Nov 2012
NCT00238732Completed650Est. Mar 2007
Peptonic Medical
Peptonic MedicalSweden - Stockholm
3 programs
2
Oxytocin 100 i.u.Phase 21 trial
VagitocinPhase 21 trial
VagivitalN/A1 trial
Active Trials
NCT03998722Completed31Est. Jun 2020
NCT01987804Completed64Est. Jan 2013
NCT01975129Completed12Est. Feb 2014
AB Science
AB ScienceFrance - Paris
1 program
1
oxytocinPhase 21 trial
Active Trials
NCT02497547Completed227Est. Jul 2015
Viramal
ViramalUK - London
1 program
VML-0001N/A1 trial
Active Trials
NCT03770065Completed14Est. Apr 2020
Walden Biosciences
Walden BiosciencesMA - Cambridge
1 program
Votiva RFN/A1 trial
Active Trials
NCT03520426Unknown50Est. Jan 2020
Quanta Therapeutics
Quanta TherapeuticsCA - South SF
1 program
Youlaser MT Group 2N/A1 trial
Active Trials
NCT03956563Unknown30Est. Aug 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Stratpharma7-940
PfizerBazedoxifene/Conjugated Estrogen
AB Scienceoxytocin
Peptonic MedicalVagitocin
Peptonic MedicalOxytocin 100 i.u.
PfizerBazedoxifene/Conjugated Estrogen
Peptonic MedicalVagivital
Quanta TherapeuticsYoulaser MT Group 2
ViramalVML-0001
Walden BiosciencesVotiva RF

Clinical Trials (10)

Total enrollment: 1,090 patients across 10 trials

ASSIST-VLA: Assessment of Symptom-Specific Improvement in Diagnosed Vaginal Atrophy Following Laser Therapy

Start: Aug 2025Est. completion: Apr 202610 patients
Phase 4Recruiting
NCT00238732PfizerBazedoxifene/Conjugated Estrogen

Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Vasomotor Symptoms Associated With Menopause

Start: Oct 2005Est. completion: Mar 2007650 patients
Phase 3Completed

An Efficacy Study of Vagitocin in Postmenopausal Women With Symptoms of Vaginal Atrophy

Start: Oct 2014Est. completion: Jul 2015227 patients
Phase 2Completed

A Pharmacokinetic Study of Vaginally and Intravenously Administered Oxytocin

Start: Sep 2013Est. completion: Feb 201412 patients
Phase 2Completed

Dose-relationship of Vaginally Administrated Oxytocin in Postmenopausal Women

Start: Jan 2012Est. completion: Jan 201364 patients
Phase 2Completed
NCT01634789PfizerBazedoxifene/Conjugated Estrogen

A Pilot Bioavailability Study of 3 Test Tablet Formulations of Bazedoxifene Compared With A Reference Tablet Formulation of Bazedoxifene/Conjugated Estrogens in Healthy Postmenopausal Women

Start: Aug 2012Est. completion: Nov 20122 patients
Phase 1Terminated

Evaluation of VagiVital® for Treatment of Vaginal Atrophy

Start: Jun 2019Est. completion: Jun 202031 patients
N/ACompleted

Effect of Hybrid Laser 10600+1540 nm on GSM

Start: May 2019Est. completion: Aug 202030 patients
N/AUnknown

Exploratory Study on Two Different Doses of VML-0001 on the Effects on Vaginal pH in Healthy Post-Menopausal Women

Start: Nov 2018Est. completion: Apr 202014 patients
N/ACompleted

Evaluation of Efficacy and Safety of Votiva for Vaginal Rejuvenation

Start: Mar 2018Est. completion: Jan 202050 patients
N/AUnknown

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 1,090 patients
7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.